Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653538 | 0.94 | CISD2 (0.41) | CISD2AAK1CA12CA1CA9 | |
| SCHEMBL7682127 | 0.86 | CA12 (0.43) | CISD2CA12CA1CA9LCK | |
| SCHEMBL15584089 | 0.84 | AAK1 (0.42) | AAK1CA1NPSR1SMN1; SMN2 | |
| SCHEMBL4212736 | 0.82 | CA12 (0.41) | CISD2AAK1CA12CA1CA9 | |
| SCHEMBL4202989 | 0.82 | AAK1 (0.43) | CISD2AAK1CA12CA1CA9 | |
| SCHEMBL19605440 | 0.81 | ALDH1A1 (0.47) | CISD2AAK1CA12CA1CA9 | |
| SCHEMBL12072957 | 0.81 | LCK (0.41) | AAK1CA12CA1CA9LCK | |
| SCHEMBL14691487 | 0.79 | LMNA (0.43) | CISD2AAK1CA12CA1CA9 | |
| SCHEMBL1322145 | 0.79 | MAPT (0.54) | CISD2AAK1CA12CA1CA9 | |
| SCHEMBL655194 | 0.79 | POLB (0.48) | CA12CA1CA9LCKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | NEUROGENETIC PHARMACEUTICALS, INC | 2010-12-30 | — | — | US | disclosed |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | NEUROGENETIC PHARMACEUTICALS, INC | 2010-12-30 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1628666-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | Torreypines Therapeutics, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | SIROCCO THERAPEUTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2004110350-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110350-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | APP, BACE1, BACE2 | CISD2 3390/4885AAK1 1434/4885CA12 2005/4885 |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | APP, BACE1, BACE2 | CISD2 3390/4885AAK1 1434/4885CA12 2005/4885 |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | APP, BACE1, BACE2 | CISD2 3390/4885AAK1 1434/4885CA12 2005/4885 |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | HYPK, APP, NEFM | CISD2 3765/4885AAK1 15/4885CA12 4113/4885 |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | PSEN2, APP, BACE1 | CISD2 2385/4885AAK1 51/4885CA12 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.